	US 12,221,615 B2
	GLP-1 and use thereof in compositions for treating metabolic diseases
Christian Hinderer, Philadelphia, PA (US); James M. Wilson, Philadelphia, PA (US); and Matthew Wilson, Philadelphia, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Appl. No. 15/750,240
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
PCT Filed Aug. 5, 2016, PCT No. PCT/US2016/045696 § 371(c)(1), (2) Date Feb. 5, 2018, PCT Pub. No. WO2017/024198, PCT Pub. Date Feb. 9, 2017.
Claims priority of provisional application 62/356,289, filed on Jun. 29, 2016.
Claims priority of provisional application 62/201,803, filed on Aug. 6, 2015.
Prior Publication US 2018/0230488 A1, Aug. 16, 2018
Int. Cl. C12N 15/86 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 48/00 (2006.01); A61P 3/10 (2006.01); C07K 14/00 (2006.01); C07K 14/605 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 48/00 (2013.01); A61K 48/005 (2013.01); A61K 48/0058 (2013.01); A61P 3/10 (2018.01); C07K 14/00 (2013.01); C07K 14/605 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01); C12N 2800/22 (2013.01)]

20 Claims

1. A recombinant adeno-associated virus (AAV) vector useful for treating diabetes in a feline comprising a nucleic acid molecule comprising a sequence encoding a propeptide and a GLP-1 peptide, wherein the propeptide is a feline clotting factor II propeptide, wherein the feline clotting factor II propeptide is amino acids 1-43 of SEQ ID NO: 24, and the GLP-1 peptide is SEQ ID NO: 1 and wherein the nucleic acid sequence encoding the GLP-1 peptide is SEQ ID NO: 2.